Comprehensive molecular detection system- Accurately comply personalized medical technology

2020-09-04

There is a growing number of pharmaceutical companies developing new drugs for targeted therapy based on somatic gene mutation. However, many limitations arise because of the poor diagnosis on molecular level. The specificity of diagnosis for different mutations and the accuracy with suitable techniques with low costs are imperative and benefit for rudderless patients. Therefore, Feng chi biotech provides various technology and diagnostic reagents, Agena bioscience MassARRAY, Whole Exon Sequence (WES), ArcherDX technical platform coupled with NGS for clinical use . These new approaches significantly improve the price-performance compared to older ways and make a breakthrough for those limitations of cancer diagnosis.

1. Agena bioscience MassARRAY provides flexible high-throughput sample verification, besides, multiplex panel makes the cost of testing super-friendly!

2. Whole Exome Sequencing (WES)-Taiwanese local service, greatly shortening TAT!

3. ArcherDX technology platform-TNA detection includes all nucleic acid mutations, a major technological breakthrough in cancer concomitant diagnosis!

Integrate the product advantages of MassARRAY, WES and ArcherDX

Accurately quantitative
Unknown Fusion gene detection
Verification for high-throughput samples
High sensitivity、low mistake rate
Simple experimental protocol
Data analysis

Agena bioscience MassARRAY, Whole Exon Sequence (WES), ArcherDX technical platform provide service and diverse application for distributors/agents、biotech companies、hospital and academic/research units.

Booth No. L231a